欧盟法规
C&L通报上下游产品
CAS号16817-43-9 5-溴-2-氯苯甲醚 | CAS号121-43-7 硼酸三甲酯 | CAS号50638-47-6 2-氯-4-溴苯甲醚 | CAS号161949-50-4 2-氯-5-碘苯甲醚合成工艺路线路线简述
- 627525-96-6 + 1165936-01-5 = 89694-47-3 + 175883-60-0
反应条件:1.1 Reagents: Sodium Periodate Solvents: Tetrahydrofuran,Water; 30 Min,Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; 17 H,Rt
标题:Regioselective Synthesis Of O-Benzenediboronic Acids Via Ir-Catalyzed O-C-H Borylation Directed By A Pyrazolylaniline-Modified Boronyl Group
作者:Yamamoto,Takeshi; Ishibashi,Aoi; Suginome,Michinori
参考文献:Organic Letters 日期:2017 卷标:19(4) 页码:886-889
📜5-溴-2-氯苯甲醚置于正丁基锂,硼酸三异丙酯,盐酸体系中,用 乙醚,正己烷,水 作为反应溶剂,化学反应 2.5H,以900 Mg的收率获得产物4-氯-3-甲氧基苯硼酸
参考文献: Heterocyclic Compounds And Methods Of Use[fr] Composés Hétérocycliques Et Procédés D'Utilisation
标题: Heterocyclic Compounds And Methods Of Use[fr] Composés Hétérocycliques Et Procédés D'Utilisation
摘要:本申请公开了抑制btk的化合物,抑制ρβKδ的化合物,以及既是btk又是pi3Kδ的双重抑制剂的化合物.还描述了合成这些抑制剂的方法,以及利用这些抑制剂治疗疾病的方法,其中抑制btk和pi3Kδ对患有该疾病的患者提供治疗益处.
海关参考信息
- 2903919090-氯苯
2905110000-甲醇
2908199090-其他酚的卤化衍生物
2908999090-其他酚的硝化衍生物 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12150934-B2
优先权日:2016-11-30
标 题 :Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
发明人:SIDDIQUI ARSHAD M; CIBLAT STEPHANE; CONSTANTINEAU-FORGET LEA; GRAND-MAITRE CHANTAL; GUO XIANGYU; SRIVASTAVA SANJAY; SHIPPS GERALD W; COOPER ALAN B; OZA VIBHA; KOSTURA MATTHEW W; LUTHER MICHAEL; LEVINE JEDD
权利人:BANTAM PHARMACEUTICAL LLC
摘要:Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by “aâ€?, R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.